Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Intercept Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Intercept Pharmaceuticals' CEO'su Jerry Durso, Jan2021 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 4.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16% maaş ve 84% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler $ 984.47K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 8.7 yıldır.
Anahtar bilgiler
Jerry Durso
İcra Kurulu Başkanı
US$4.5m
Toplam tazminat
| CEO maaş yüzdesi | 16.0% |
| CEO görev süresi | 2.8yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 2.7yrs |
| Yönetim Kurulu ortalama görev süresi | 8.7yrs |
Son yönetim güncellemeleri
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
May 11CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$159m |
| Mar 31 2023 | n/a | n/a | -US$173m |
| Dec 31 2022 | US$4m | US$715k | -US$175m |
| Sep 30 2022 | n/a | n/a | -US$202m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$8m | US$691k | -US$136m |
| Sep 30 2021 | n/a | n/a | -US$144m |
| Jun 30 2021 | n/a | n/a | -US$193m |
| Mar 31 2021 | n/a | n/a | -US$231m |
| Dec 31 2020 | US$4m | US$600k | -US$273m |
| Sep 30 2020 | n/a | n/a | -US$321m |
| Jun 30 2020 | n/a | n/a | -US$339m |
| Mar 31 2020 | n/a | n/a | -US$347m |
| Dec 31 2019 | US$4m | US$573k | -US$345m |
| Sep 30 2019 | n/a | n/a | -US$335m |
| Jun 30 2019 | n/a | n/a | -US$314m |
| Mar 31 2019 | n/a | n/a | -US$318m |
| Dec 31 2018 | US$3m | US$541k | -US$309m |
| Sep 30 2018 | n/a | n/a | -US$333m |
| Jun 30 2018 | n/a | n/a | -US$341m |
| Mar 31 2018 | n/a | n/a | -US$352m |
| Dec 31 2017 | US$4m | US$441k | -US$360m |
Tazminat ve Piyasa: Jerry 'nin toplam tazminatı ($USD 4.46M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).
Tazminat ve Kazançlar: Jerry 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Jerry Durso (55 yo)
2.8yrs
Görev süresi
US$4,455,463
Tazminat
Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.8yrs | US$4.46m | 0.12% $ 984.5k | |
| Chief Financial Officer | 2.4yrs | US$1.39m | 0.055% $ 437.4k | |
| General Counsel | 2.8yrs | US$1.31m | 0.13% $ 1.1m | |
| Executive VP & Chief Commercial Officer | 2.8yrs | US$1.34m | 0.040% $ 317.4k | |
| President of Research & Development and Chief Medical Officer | 2.4yrs | US$1.61m | 0.068% $ 538.6k | |
| Chief Accounting Officer & Treasurer | 2.7yrs | US$856.23k | 0.061% $ 483.6k | |
| Executive Director of Global Investor Relations | 1.9yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | 6.5yrs | US$1.91m | 0.036% $ 285.7k | |
| Founder | 2.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Senior Vice President of Regulatory Affairs | no data | Veri yok | Veri yok | |
| Chief Quality Officer & SVP of Technical Operations | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Corporate Affairs | less than a year | Veri yok | Veri yok |
2.7yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: ICPT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.5yrs | US$4.46m | 0.12% $ 984.5k | |
| Founder | 21.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Independent Chairman | 7.3yrs | US$327.39k | 0.056% $ 447.4k | |
| Independent Director | 9.8yrs | US$332.39k | 0.056% $ 445.5k | |
| Independent Director | 9.3yrs | US$327.39k | 0.061% $ 484.3k | |
| Independent Director | 11.1yrs | US$317.39k | 0.091% $ 719.8k | |
| Lead Independent Director | 8yrs | US$337.39k | 0.057% $ 449.2k | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 7.3yrs | US$322.39k | 0.059% $ 469.7k |
8.7yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ICPT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.7 yıldır).